TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

150 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • COPD (chronic lung disease)

    A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

    Testing two doses of a medicine versus placebo for COPD symptoms

    📍 Research Site · Birmingham, AL · +39 more US sites · Get directions →

    This Phase IIb dose-ranging study will evaluate the efficacy and safety of 2 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.

    ✓ Study care freePhase 2Ages 40+Learn more →
  • Kidney disease

    Oral Intradialytic Amino Acid Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis

    Testing amino acid supplements during hemodialysis for fatigue and thinking in end-stage kidney

    📍 The University of Texas Health Science Center at San Antonio · San Antonio, TX · Get directions →

    The study will test and compare the efficacy of a single essential amino acid valine with a combination of essential amino acids (EAA) supplement on fatigue, frailty, and cognitive function in end-stage kidney disease (ESKD) patients undergoing hemodialysis (HD) treatment.

    ✓ Study care freeEarly Phase 1Ages 18–64Learn more →
  • Kidney disease

    📍 Mayo Clinic in Arizona · Scottsdale, AZ · +4 more US sites · Get directions →

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Kidney disease

    A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

    Testing whether empagliflozin is safe and helps children with chronic kidney disease

    📍 University of Alabama at Birmingham · Birmingham, AL · +29 more US sites · Get directions →

    This study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medicine called empagliflozin helps children and adolescents with CKD.

    ✓ Study care freePhase 3Ages 2–17Learn more →
  • Kidney disease

    Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD

    Studying how blood vessel and nerve control during exercise works in people with chronic kidney

    📍 Emory Clinic · Atlanta, GA · +1 more US site · Get directions →

    The goals of this project are to investigate the mechanisms and potential therapies related to exercise capacity in persons with chronic kidney disease (CKD).

    ✓ Study care freePhase 2Ages 40–75Learn more →
  • COPD (chronic lung disease)

    Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency

    Testing how a genetic change in alpha-1 antitrypsin affects immune and lung responses to a pneumonia

    📍 University of Alabama at Birmingham · Birmingham, AL · Get directions →

    The goal of this study is to learn whether patients who have a genetic mutation in the genes that cause alpha 1 antitrypsin deficiency also have genetic variation in nearby genes that can increase risk for reduced immune function and respiratory infections. To investigate this hypothesis, we will compare immune responses to the 20-valent pneumococcal conjugate vaccine (PCV20, Pfizer) between participants who have one abnormal copy of the SERPINA1 gene and either no COPD exacerbations, vs those with 2 or more COPD exacerbations in the past year.

    ✓ Study care freePhase 4Ages 19+Learn more →
  • COPD (chronic lung disease)

    📍 University of Alabama at Birmingham- Site Number : 8400003 · Birmingham, AL · +39 more US sites · Get directions →

    This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. Participation to the study consists of 3 periods: * Screening period of up to 4 weeks * Randomized intervention period of approximately 48 weeks * Follow-up period: Approximately 8 weeks The study duration will be up to 60 weeks.

    ✓ Study care freePhase 3Ages 40–80Learn more →
  • High blood pressureKidney disease

    📍 Research Site · Surprise, AZ · +17 more US sites · Get directions →

    International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney disease and high blood pressure.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • COPD (chronic lung disease)

    A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

    Testing the long-term safety of astegolimab in people with COPD

    📍 UAB Lung Health Center · Birmingham, AL · +39 more US sites · Get directions →

    The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.

    ✓ Study care freePhase 3Ages 40–90Learn more →
  • Heart / cardiovascular diseaseKidney disease

    A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

    Testing whether orforglipron changes heart outcomes in adults with heart disease and/or kidney

    📍 Instituto de Investigaciones Clínicas Bahia Blanca · Bahía Blanca, · Get directions →

    The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.

    ✓ Study care freePhase 3Ages 50+Learn more →
  • Kidney disease

    CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

    Comparing how two beta-blockers work in hemodialysis patients on heart outcomes

    📍 VA Long Beach Healthcare System, Long Beach, CA · Long Beach, CA · +7 more US sites · Get directions →

    The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • COPD (chronic lung disease)

    A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

    Testing whether tezepelumab is safe and works for adults with COPD

    📍 Research Site · Foley, AL · +39 more US sites · Get directions →

    A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

    ✓ Study care freePhase 3Ages 40–80Learn more →
  • Kidney disease

    The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

    Testing a 12-week diabetes medicine combination in kidney transplant patients with kidney disease

    📍 Toronto General Hospital · Toronto, Ontario · Get directions →

    The study aims to determine the short-term efficacy, mechanisms and safety of 12 weeks of dapagliflozin and semaglutide combination therapy in 20 KTR, with and without T2D.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Kidney disease

    Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD

    Testing whether empagliflozin changes kidney filter injury proteins in African American Veterans

    📍 Washington DC Veterans Affairs Medical Center (688) · Washington D.C., DC · Get directions →

    Primary Objective:To study podocyte specific injury markers in African American Veterans with non-diabetic kidney disease(NDKD), on empagliflozin therapy. Primary Endpoint: Assess the effect of Empagliflozin on podocyte-specific proteins in exosomes isolated from subjects' urine, such as nephrin, podocalyxin and Wilms'Tumor (WT-1) protein.

    ✓ Study care freePhase 4Ages 19–90Learn more →
  • Kidney disease

    Acute Equol Supplementation and Vascular Function in Women With and Without CKD

    Testing whether taking equol affects blood vessel function in women with or without CKD

    📍 University of Colorado Anschutz Medical Campus · Aurora, CO · Get directions →

    The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk.

    ✓ Study care freePhase 2Ages 50–69WomenLearn more →
  • Kidney disease

    📍 SouthCoast Research Center, Inc. · Miami, FL · +1 more US site · Get directions →

    The goal of this clinical trial is to learn about the safety (good or bad) of giving two AION-301 intravenous (IV) infusions, in adults with Stage 3 Chronic Kidney Disease (CKD). It will also help to learn if AION-301 reduces the symptoms of CKD and/or progression.

    ✓ Study care freePhase 1Ages 35–75Learn more →
  • Sickle cell disease

    A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)

    Testing the safety and how an oral carbon monoxide liquid works in sickle cell disease

    📍 Cevaxin - The Panama Clinic · Panama City, · Get directions →

    This is a multi-center, open label Phase 2a clinical trial in subjects with sickle cell disease to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of HBI-002, an orally administered liquid containing carbon monoxide (CO), with doses daily for 14 days.

    ✓ Study care freePhase 1Ages 18–55Learn more →
  • COPD (chronic lung disease)Asthma

    The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)

    Testing whether positive airway pressure helps a lung medicine (NAC) reach mucus plugs in asthma or

    📍 UCSF Airway Clinical Research Center · San Francisco, CA · Get directions →

    The goal of this clinical trial is to determine if positive pressure during inspiration will improve penetration of aerosolized N-Acetylcysteine (NAC) into airway mucus plugs in the lungs of patients with asthma or Chronic Obstructive Pulmonary Disease (COPD). The main questions it aims to answer are: * Does delivery of aerosolized NAC with positive inspiratory pressure have a greater effect on mucus plug burden in the lungs than delivery of NAC without positive pressure.

    ✓ Study care freePhase 4Ages 18–85Learn more →
  • Sickle cell disease

    Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults

    Testing whether a low dose of ketamine helps treat sickle cell pain in children and young adults

    📍 Harbor UCLA Medical Center · Torrance, CA · Get directions →

    The purpose of this research is to see if ketamine is effective and safe in treating children and young adults with sickle cell disease experiencing sickle cell related pain. In this study, we will compare the outcomes (such as pain scores) in persons who receive standard of care pain medicine (an opioid such as morphine) plus a low dose (amount) of ketamine to those who receive only standard of care pain medicine.

    ✓ Study care freePhase 2Ages 5–20Learn more →
  • Kidney disease

    Intradialytic Exercise Combined With Creatine Monohydrate in Patients With Chronic Kidney Disease Undergoing Hemodialysis.

    Testing whether exercise during dialysis and creatine help people with chronic kidney disease

    📍 IMSS-Bienestar State Haemodialysis Centre · Colima, Coliima · Get directions →

    This study aims to evaluate the effects of creatine monohydrate supplementation and an intradialytic exercise program on body composition, biochemical parameters, and functional capacity in patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis. The study will compare the independent and combined effects of these interventions over an 8-week period to determine their potential benefits in this patient population.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • COPD (chronic lung disease)

    📍 GSK Investigational Site · Sheffield, AL · +39 more US sites · Get directions →

    Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.

    ✓ Study care freePhase 3Ages 40–80Learn more →
  • Sickle cell disease

    The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

    Testing rilzabrutinib for safety and effectiveness in sickle-cell disease

    📍 University of Alabama at Birmingham- Site Number : 8400003 · Birmingham, AL · +15 more US sites · Get directions →

    This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-adaptive, group-sequential study (Part A), followed by an open-label LTE period (Part B) to investigate the efficacy, and safety of rilzabrutinib in participants with sickle-cell disease (SCD). Study details include: * Study duration: a 52-week double-blind period (Part A), followed by an open-label LTE period (Part B).

    ✓ Study care freePhase 3Ages 10–65Learn more →
  • COPD (chronic lung disease)

    To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

    Testing two doses of a daily medicine versus placebo in people with COPD over 52 weeks

    📍 DM Clinical Research - Phoenix · Phoenix, AZ · +11 more US sites · Get directions →

    This is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD. Study participants will be randomized to receive either study drug or placebo administered once daily for 52 weeks.

    ✓ Study care freePhase 2Ages 40–85Learn more →
  • Kidney disease

    Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease

    Testing kidney disease drug effects and safety in teens with early CKD

    💵 May compensate

    📍 Instituto de atención Integral de Enfermedades Renales del Estado de Aguascalientes · Aguascalientes, Aguascalientes · Get directions →

    Chronic kidney disease (CKD) is highly prevalent in the state of Aguascalientes, Mexico, particularly among adolescents and young adults. Epidemiologic and histologic studies suggest that this burden is largely driven by reduced nephron endowment of prenatal origin, leading to compensatory glomerular hyperfiltration, adaptive podocytopathy, and persistent albuminuria at early stages of disease.

    ✓ Study care freePhase 4Ages 14–18Learn more →
  • Sickle cell disease

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

    Testing whether extra arginine lowers pain in children with sickle cell

    📍 Children's Healthcare fo Atlanta at Hughes Spalding · Atlanta, GA · +1 more US site · Get directions →

    The purpose of this study is to determine whether giving extra arginine to patients with sickle cell disease seeking treatment for vaso-occlusive painful events (VOE) will decrease pain scores, decrease need for pain medications or decrease length of hospital stay or emergency department visit.

    ✓ Study care freePhase 1Ages 7–21Learn more →
  • Kidney disease

    Randomised Evaluation of Sodium Dialysate Levels on Vascular Events

    Testing whether two dialysate salt levels affect heart events and death

    📍 Royal Adelaide Hospital · Adelaide, · Get directions →

    This global study will assess the effect of randomising dialysis sites to one of two default dialysate sodium concentrations in current practice, 140mmol/l and 137mmol/l, on major cardiovascular events and death in patients receiving maintenance haemodialysis.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Sickle cell disease

    A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease

    Testing a once-daily mouth medicine in teens with sickle cell disease

    📍 The Hospital for Sick Children · Toronto, Ontario · Get directions →

    This study is being done to learn about etavopivat, a once a day medicine taken by mouth in adolescents with sickle cell disease. The main goals are to study safety and how long etavopivat stays in the bloodstream, while also studying if there are benefits from taking etavopivat.

    ✓ Study care freePhase 2Ages 1–18Learn more →
  • Kidney disease

    A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

    Testing etelcalcetide in children with kidney disease on dialysis

    📍 Childrens Hospital of Los Angeles · Los Angeles, CA · +9 more US sites · Get directions →

    This is a phase 3 trial of etelcalcetide in pediatric participants with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) on hemodialysis.

    ✓ Study care freePhase 3Learn more →
  • Type 2 diabetesKidney disease

    Mechanism of SGLT2 Inhibition in the Kidney

    Testing how SGLT2 medicines affect kidney function in type 2 diabetes

    💵 May compensate

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    The goal of this open-label, non-randomized clinical trial is to determine what effects, if any, an FDA-approved drug class known as SGLT2 inhibitors (Canagliflozin or INVOKANA) has any protective effects on kidney function in Type 2 diabetes. We are looking for participants 18-80 years of age, who have had a clinical diagnosis of Type 2 diabetes for ≥ 3 years.

    ✓ Study care freePhase 4Ages 18–80Learn more →
  • Kidney disease

    A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

    Testing safety and effects on urine protein in adults with APOL1 kidney disease

    📍 Research Site · Decatur, AL · +39 more US sites · Get directions →

    This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease

    ✓ Study care freePhase 2Ages 18–68Learn more →
  • Kidney disease

    Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial

    Testing medicines before surgery to reduce bleeding in kidney patients

    📍 London Health Sciences Centre · London, Ontario · Get directions →

    The BRACKETS pilot study is a multicentre, prospective, randomized controlled trial of prophylactic preoperative tranexamic acid (TXA) versus placebo and, using a partial factorial design, of prophylactic preoperative desmopressin versus placebo.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Kidney disease

    Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

    Testing long-term safety and effectiveness of zigakibart in adults with IgA kidney disease

    📍 Colorado Kidney Care Nephrology · Denver, CO · +6 more US sites · Get directions →

    The purpose of this study is to determine if zigakibart is safe and effective for long-term use in patients with immunoglobulin A nephropathy (IgAN). This is an extension study for patients who have already completed an another zigakibart study.

    ✓ Study care freePhase 3Ages 18–100Learn more →
  • Sickle cell disease

    RH Genotype Matched RBC Transfusions

    Testing whether matching donor red blood cells by RH type helps people with sickle cell who need

    📍 Children's Hospital of Philadelphia · Philadelphia, PA · Get directions →

    To determine the feasibility and efficacy of matching donor red cells by RH genotype for a cohort of chronically transfused patients with SCD.

    ✓ Study care freePhase 1Ages 1+Learn more →
  • Kidney disease

    Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine

    Testing colchicine for safety and effects in people with chronic kidney disease

    📍 Brigham and Women's Hospital · Boston, MA · Get directions →

    This study is designed to determine the efficacy and safety of colchicine in patients with chronic kidney disease.

    ✓ Study care freePhase 2Ages 21–80Learn more →
  • COPD (chronic lung disease)

    Multi-Center Clean Air Randomized Controlled Trial in COPD

    Testing whether using an air cleaner improves COPD symptoms and quality of life

    📍 University of Alabama, Lung Health Center · Birmingham, AL · +10 more US sites · Get directions →

    This is a multi-center randomized, sham-controlled clinical trial to determine the effectiveness of an air cleaner intervention aimed at improving indoor air quality on reducing COPD exacerbation risk and improving quality of life, functional status, rescue medication use.

    ✓ Study care freePhase 3Ages 40+Learn more →
  • Kidney disease

    Concomitant Renal and Urinary Bladder Allograft Transplantation

    Testing whether transplanting a new kidney and bladder at the same time is possible for people with

    📍 Mayo Clinic · Rochester, MN · +1 more US site · Get directions →

    The purpose of this study is to establish if concomitant renal and vascularized urinary bladder allograft transplantation is feasible.

    ✓ Study care freeEarly Phase 1Ages 1–60Learn more →
  • High blood pressureCOPD (chronic lung disease)

    Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH

    Testing tadalafil to see if it improves shortness of breath in COPD with high blood pressure in the

    📍 Rocky Mountain Regional VA Medical Center, Aurora, CO · Aurora, CO · +4 more US sites · Get directions →

    The investigators will study whether the drug tadalafil improves shortness of breath in 126 Veterans with Chronic Obstructive Pulmonary Disease (COPD) and high blood pressure in the lungs. The investigators will also assess whether tadalafil improves quality of life, home daily physical activity, exercise endurance, the frequency of acute flares of COPD, blood pressure in the lungs, and lung function.

    ✓ Study care freePhase 2Ages 35–89Learn more →
  • Sickle cell disease

    Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease

    Testing a one-time blood stem cell transplant using gene editing for severe sickle cell disease

    📍 University of California, Los Angeles · Los Angeles, CA · +1 more US site · Get directions →

    This is an open label, non-randomized, 2-center, phase 1/2 trial of a single infusion of sickle allele modified cluster of differentiation (CD34+) hematopoietic stem progenitor cells (HSPCs) in subjects with in subjects ≥12 years old to 35 years old severe Sickle Cell Disease (SCD). The study will evaluate the hematopoietic stem cell transplantation (HSCT) using CRISPR/Cas9 edited red blood cells (known as CRISPR\_SCD001 Drug Product).

    ✓ Study care freePhase 1Ages 12–35Learn more →
  • COPD (chronic lung disease)

    📍 Chandler Clinical Research Trials- Site Number : 8400025 · Chandler, AZ · +39 more US sites · Get directions →

    This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive) with inadequately controlled Chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype. Participation to the study consists of 3 periods: * Screening period of up to 4 weeks * Randomized intervention period of approximately 48 weeks * Follow-up period: Approximately 8 weeks The study duration will be up to 60 weeks.

    ✓ Study care freePhase 3Ages 40–80Learn more →
  • Kidney disease

    Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease

    Testing whether a trial of SGLT2 inhibitors in youth with chronic kidney disease is feasible

    📍 Ann & Robert H. Lurie Children's Hospital of Chicago · Chicago, IL · Get directions →

    The goal of this study is to learn if a clinical trial of sodium-glucose co-transporter 2 inhibitors (SGLT2i) is possible in youth with chronic kidney disease (CKD). The investigators also plan to explore whether treatment with SGLT2i (Empagliflozin) helps improve risk factors for worsening kidney and heart disease.

    ✓ Study care freeEarly Phase 1Ages 12–25Learn more →
  • Heart / cardiovascular diseaseKidney disease

    Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

    Testing whether sotagliflozin can slow kidney damage in type 1 diabetes

    💵 May compensate

    📍 Stanford University Medical Center · Stanford, CA · +12 more US sites · Get directions →

    Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of substances called ketone bodies) observed with SGLT2i therapy in T1D.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Kidney disease

    Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD

    Testing a GE xenokidney transplant in people with ESRD for safety and effectiveness

    📍 Northwestern Memorial Hospital · Chicago, IL · +1 more US site · Get directions →

    The purpose of this study is to evaluate the safety and efficacy of the 10 GE Xenokidney in patients with ESRD who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2). The study consists of xenotransplantation followed by a 24-week Post-transplant Follow up Period (Part A) to evaluate the efficacy and safety objectives followed by a Long-term Follow-up Period (Part B) to evaluate participant survival, 10 GE Xenokidney survival, and screening for zoonotic infections.

    ✓ Study care freePhase 1Ages 40–70Learn more →
  • Kidney disease

    Bone in CKD Alkali Response (BICARb Pilot Trial)

    Testing whether potassium citrate improves bone health in people with chronic kidney disease

    📍 Albert Einstein College of Medicine · The Bronx, NY · +1 more US site · Get directions →

    The goal of this clinical trial is to test whether potassium citrate improves skeletal health in adults and children with chronic kidney disease. The main questions it aims to answer are: * To evaluate effects of potassium citrate treatment on bone quality and strength.

    ✓ Study care freePhase 2Ages 5–100Learn more →
  • Sickle cell disease

    Cannabidiol in Sickle Cell Disease

    Testing twice-daily cannabidiol doses for people with sickle cell disease

    📍 Icahn School of Medicine at Mount Sinai · Manhattan, NY · Get directions →

    Randomized, placebo-controlled, double masked, dose finding study of twice daily cannabidiol given at 3 dose levels, 200mg, 400mg, and 600mg, compared to placebo for 4 weeks.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • COPD (chronic lung disease)

    Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)

    Testing an add-on treatment for adults having a COPD flare with type 2 inflammation

    📍 University of Alabama at Birmingham Lung Health Center · Birmingham, AL · +21 more US sites · Get directions →

    This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Type 2 diabetesKidney disease

    Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease

    Testing whether people with type 2 diabetes have early hormone-related kidney risk

    📍 Brigham and Women's Hospital · Boston, MA · Get directions →

    The aim of this protocol is to assess the presence and severity of primary aldosteronism pathophysiology in patients with type 2 diabetes who have, or are at-risk for developing, chronic kidney disease.

    ✓ Study care freeEarly Phase 1Ages 18–80Learn more →
  • COPD (chronic lung disease)

    Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)

    Testing an add-on medicine to treat moderate to severe COPD with type 2 inflammation

    📍 GSK Investigational Site · Loxahatchee Groves, FL · +3 more US sites · Get directions →

    Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.

    ✓ Study care freePhase 3Ages 40–80Learn more →
  • Sickle cell disease

    Early Screening and Treatment of Heart Complication in Sickle Cell Disease

    Testing early heart screening and iron overload treatment in people with sickle cell disease

    📍 Inova Schar Cancer · Fairfax, VA · +1 more US site · Get directions →

    This study tests whether early heart screening and treatment for iron overload in subjects with sickle cell disease can prevent heart problems and reduce hospitalizations.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Sickle cell disease

    Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease

    Testing whether routine red blood cell transfusions in pregnancy reduce sickle cell flare-ups or

    📍 Grady Health System · Atlanta, GA · Get directions →

    The goal of this study is to determine if there is a positive effect of prophylactic red blood cell (RBC) transfusion of leukoreduced, ABO, Rh (D/Cc/Ee) and Kell matched blood compared to standard of care on the number of episodes of acute sickle cell disease (SCD) manifestations or pregnancy-related complications requiring acute health care encounters (acute care/ER/Hospital visits) or resulting in death over the entirety of pregnancy until 2 months post-partum in women with SCD. RBC transfusion is the only disease-modifying therapy for pregnant women with SCD, and it is considered a standard treatment option however, there exists no consensus on the role of transfusion therapy in preventing SCD-related pregnancy complications.

    ✓ Study care freePhase 4Ages 18+WomenLearn more →
  • Kidney disease

    Testosterone Treatment in Men With Chronic Kidney Disease

    Testing an oral testosterone medicine to raise testosterone in men with chronic kidney disease

    📍 Saint Louis Univeristy · St Louis, MO · Get directions →

    This study in being conducted in men who have low testosterone and chronic kidney disease. The investigators will evaluate the effects of an oral testosterone preparation, JATENZO, on testosterone levels and hemoglobin (red blood cells).

    ✓ Study care freePhase 2Ages 18–85MenLearn more →
  • Sickle cell disease

    Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial

    Testing two daily doses of zinc in people with sickle cell disease to see changes in bone-related

    📍 UCSF Benioff Children's Hospital Oakland · Oakland, CA · +5 more US sites · Get directions →

    The goal of this short term prospective Phase II study is to compare the effects of two alternate daily doses of zinc (25 and 40 mg/day) in 34 randomly assigned homozygous Sickle Cell Disease (SCD-SS) patients aged 15-40 years old. The main question it aims to answer is: Which biomarkers are most responsive to zinc supplementation, and what is the maximum tolerated zinc dose that induces the desired changes in biomarkers of bone turnover?

    ✓ Study care freePhase 2Ages 15–40Learn more →
  • Sickle cell disease

    Allo HSCT for High Risk Hemoglobinopathies

    Testing donor stem cell transplant for people with high-risk sickle cell

    📍 Masonic Cancer Center · Minneapolis, MN · Get directions →

    A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.

    ✓ Study care freePhase 2Learn more →
  • Sickle cell disease

    Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

    Testing a single pneumococcal vaccine dose in children with sickle cell disease

    📍 Site # 8400006 · Atlanta, GA · +4 more US sites · Get directions →

    The purpose of this study is to measure whether PCV21 vaccine (investigational pneumococcal vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20vPCV (licensed pneumococcal vaccine) when given as a single dose to children aged 2 to 17 years with sickle cell disease who had received or not a previous vaccination with pneumococcal conjugate or pneumococcal polysaccharide vaccine.

    ✓ Study care freePhase 3Ages 2–17Learn more →
  • Kidney disease

    SAfety of Regional Citrate Anticoagulation (SARCA Study)

    Testing the safety of regional citrate blood-thinner use in adults

    📍 John L. McClellan Memorial Veterans' Hospital · Little Rock, AR · +9 more US sites · Get directions →

    This is an Open-label, Prospective, Multicenter Study to Assess the SAfety of Regional Citrate Anticoagulation Delivered by the multiFiltratePRO system in Adult Patients Requiring Continuous Renal Replacement Therapy (SARCA Study).

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Kidney disease

    EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

    Testing a treatment for adults with chronic kidney disease to help slow progression

    📍 Apogee Clinical Research · Huntsville, AL · +39 more US sites · Get directions →

    This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • COPD (chronic lung disease)

    A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

    Comparing inhalers to see how triple breathing medicine affects heart and lung outcomes in COPD

    📍 Research Site · Athens, AL · +39 more US sites · Get directions →

    This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.

    ✓ Study care freePhase 3Ages 40–80Learn more →
  • COPD (chronic lung disease)

    A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD

    Testing different doses of two inhaled medicines for COPD symptoms

    📍 SEC Clinical Research, LLC · Dothan, AL · +39 more US sites · Get directions →

    This study will assess the safety and efficacy of fixed dose combinations of ensifentrine with two different glycopyrrolate dose levels compared to placebo and to the individual components of the fixed dose combinations, each administered twice a day via standard jet nebulizer, in adult subjects with chronic obstructive pulmonary disease (COPD).

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Kidney disease

    Patient-driven Management of BP in CKD

    Testing whether pharmacist-guided blood pressure management helps CKD patients lower blood pressure

    📍 Iowa City VA Health Care System, Iowa City, IA · Iowa City, IA · Get directions →

    The proposed research will evaluate if patients managing their blood pressure medications under the guidance of a clinical pharmacist works better to lower blood pressure than patients monitoring their blood pressure at home and the standard care. 60 Veterans with chronic kidney disease (CKD) will be included in the study.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Kidney disease

    Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD

    Testing a new kidney tissue transplant to treat end-stage kidney disease

    📍 New York University Langone Health · New York, NY · Get directions →

    The purpose of this study is to evaluate the safety and efficacy of the GGTA1 KO Thymokidney in patients with end-stage renal disease (ESRD) who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2). The study consists of xenotransplantation followed by a 24-week Post-transplant Follow-up Period (Part A) to evaluate the efficacy and safety objectives followed by a Long-term Follow-up Period (Part B) to evaluate participant survival, GGTA1 KO Thymokidney survival, and screening for zoonotic infections.

    ✓ Study care freePhase 1Ages 40–70Learn more →
  • COPD (chronic lung disease)

    Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure

    Comparing inhaled triple versus double medicines for COPD lung airways after wood smoke exposure

    💵 May compensate

    📍 Insituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas" · Mexico City, Tlalpan · Get directions →

    This phase IV randomized controlled clinical trial intend to compare the effect of three close standard inhaled triple therapies and one close standard inhaled double therapy on the small airway in patients with Chronic Obstructive Pulmonary Disease (COPD-B) and chronic bronchitis without obstruction (BCNO) exposed to wood smoke. The treatment phase duration is of 3 months.

    ✓ Study care freePhase 4Ages 35–85WomenLearn more →
  • Showing the first 60 of 150. Add filters or a location to narrow down.